A new meta-analysis in JAMA Cardiology, published on October 7, 2026, pulls together 27 randomized trials and 88,830 adults to ask a question many people on blood pressure medication quietly wonder about: if your blood pressure goal is set lower, what happens to your kidneys? The short answer is nuanced. Heart events fell, kidney failure did not rise, but the eGFR number on lab reports dropped more often. This article explains what that means and which blood tests to follow.
What the new analysis found
The researchers compared intensive blood pressure targets (most often a systolic pressure below 120 or below 130 mm Hg) with standard targets, in people with and without chronic kidney disease (CKD). Trials had to last at least one year and excluded people on dialysis.
The heart benefit held up, including in CKD
For every 10 mm Hg lower systolic pressure, major cardiovascular events were about 15% less frequent. The benefit was not statistically different between people with CKD and those without. Because people with CKD start with a higher heart risk, the absolute number of events avoided was at least as large for them.
The kidney signal is more complicated
Intensive treatment did not increase kidney failure (dialysis or transplant), even after up to ten years of follow-up in some trials. It did, however, make sustained drops in eGFR more common. Drops of 30% or more were 42% more likely, and drops of 40% or more were 47% more likely. Larger drops of 50% or more were not significantly increased.
| Outcome | Intensive vs. standard target | In plain words |
|---|---|---|
| Major cardiovascular events | About 15% lower per 10 mm Hg | Fewer heart attacks, strokes and related events |
| Kidney failure | No increase | No sign that treatment pushed people to dialysis |
| Sustained eGFR drop of 30% or more | More frequent | The lab number fell, often without lasting kidney failure |
| All-cause mortality (exploratory) | Lower | A hint of benefit, not a firm conclusion |
Why your eGFR can fall when your pressure does
The authors suggest that part of the eGFR decline reflects a change in how blood flows through the kidneys once pressure is lowered, particularly when a diuretic is added. Diuretics were used more often in the intensive groups. In other words, a lower eGFR after treatment may partly be a hemodynamic effect rather than proof of damage, but the authors say they cannot fully rule out a small kidney harm.
That is why the blood test matters. Your eGFR is calculated from creatinine, age and sex, and it moves with hydration, muscle mass and medication. If you want to understand the number itself, read what your kidney filtration number tells you.
Which blood and urine tests to follow if your target is lowered
The authors recommend careful monitoring of blood pressure, eGFR and electrolytes when an intensive strategy is used. In practice, a follow-up panel after a treatment change usually looks at a few markers together.
- Creatinine and eGFR, to see how filtration changes over time. Our guide helps you understand what creatinine says about kidney function.
- Potassium and sodium, which can shift with diuretics and with some blood pressure drugs. See why the potassium blood test matters.
- The urine albumin-to-creatinine ratio, an early kidney marker that is often skipped. Learn how to read a urine albumin result.
If your treatment decision depends on a risk score built from lab values, our earlier piece explains why blood tests now shape blood pressure treatment.
How to read a change in your eGFR after a treatment change
A single value is a snapshot. The analysis counted sustained declines, meaning a drop that persists on repeat testing. The table below is a conversation guide, not a rule.
| What you see | What it may reflect | Question to ask |
|---|---|---|
| One lower eGFR after a new drug or dose | Hydration, timing, or a hemodynamic effect of treatment | When should this be rechecked? |
| Lower eGFR that stays low on repeat tests | A sustained change that deserves a closer look | Is my diuretic or dose still right for me? |
| Abnormal potassium or sodium | An electrolyte effect of the medication | Do I need a repeat panel sooner? |
| Albumin in the urine | Kidney stress that eGFR alone can miss | Should I have a urine albumin test each year? |
What this analysis cannot tell you
Some of the trials had risk-of-bias concerns, the authors worked from published trial-level data rather than individual records, and blood pressure was measured in different ways across studies. Evidence is also uncertain for people with an eGFR below 30. One of the authors stresses that a single target is not right for every person with CKD and that the decision should be personalized. For a broader view of high blood pressure, see our overview of high blood pressure causes and management.
Latest scientific advances
The 2026 meta-analysis changes the picture drawn by earlier work. A Cochrane review published in 2024, which pooled six trials in people with hypertension and CKD, found that lower targets probably made little difference to deaths or heart events, and noted that its evidence had limits, including open-label designs and office-only blood pressure readings. A 2025 meta-analysis of nine trials in CKD suggested that targeting below 130/80 mm Hg might lower the risk of death and heart events without increasing serious kidney events.
What this means for you: as more and larger trials were added, the heart benefit of a lower target became clearer, while the kidney picture stayed reassuring for kidney failure but showed more eGFR dips. The practical takeaway is not to fear a lower target, but to make sure the follow-up blood tests are actually scheduled. These are research findings, not instructions to change your treatment.
When to talk to your doctor
Ask for a follow-up plan whenever your blood pressure treatment is intensified. Contact your doctor promptly if you feel dizzy or faint, have a fall, notice much less urine than usual, or if a repeat test shows a clearly lower eGFR or an abnormal potassium. Do not stop or change blood pressure medication on your own.
Glossary
- eGFR: estimated glomerular filtration rate, a calculation of how well the kidneys filter blood, based on creatinine, age and sex.
- Meta-analysis: a study that statistically combines the results of several trials.
- Systolic blood pressure: the top number, measured when the heart contracts.
- CKD: chronic kidney disease, a lasting reduction in kidney function.
- Diuretic: a medication that helps the body remove salt and water.
- Albumin-to-creatinine ratio: a urine test that detects small amounts of albumin leaking from the kidneys.
Frequently asked questions
Does a lower blood pressure goal damage the kidneys?
In this analysis, intensive treatment did not increase kidney failure. It did make sustained eGFR declines more common, which may partly reflect a treatment effect on blood flow. Monitoring is advised.
Why did my eGFR drop after starting a new blood pressure medicine?
Several things can lower it, including a diuretic, dehydration or timing of the sample. A repeat test over time is more informative than one value.
Which blood tests should I have after my blood pressure treatment changes?
Usually creatinine with eGFR and electrolytes such as potassium and sodium, and sometimes a urine albumin-to-creatinine ratio. Your doctor decides the timing.
Is a blood pressure goal below 120 right for everyone?
No. The authors say the decision should be personalized, particularly in people with CKD and when the eGFR is below 30.
Can I rely on a home reading to reach the target?
Trials measured blood pressure in different ways, so targets from studies do not map exactly onto home or pharmacy readings. Discuss how to measure with your clinician.
Sources
- Iatridi F, Roddick AJ, Staplin N, et al. Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease. JAMA Cardiology, October 2026
- Cochrane Database of Systematic Reviews: Blood pressure targets for hypertension in people with chronic renal disease (2024)
- Hypertension Research: Evaluating blood pressure targets in chronic kidney disease, a systematic review and meta-analysis (2025)
- Managed Healthcare Executive: coverage of the JAMA Cardiology meta-analysis
- Pharmacy Times: coverage of the JAMA Cardiology meta-analysis
- NIDDK: Estimated Glomerular Filtration Rate calculators
- MedlinePlus: Estimated Glomerular Filtration Rate (eGFR) and GFR tests
- CDC: About High Blood Pressure
Other articles
- Kidney function tests for people with heart disease
- The kidney function panel explained
- Undiagnosed high blood pressure
- The electrolyte panel explained
Understand your own blood test results with AI DiagMe
Upload your creatinine, eGFR and electrolyte results and get a clear, doctor-validated explanation in minutes. Understand your lab results with AI DiagMe.
